Quintrio
Home

SERVICES-MEDICAL LABORATORIES

Exagen Inc. Common Stock

XGN

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

Last trade $3.79
Day change +$0.02 (+0.53%)
Day range $3.64 – $3.92
Volume 695,728
Market cap $96M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$96.19M
Price / earnings
—
Price / book
6.98×
Price / sales
1.33×
EV / sales
1.29×
EV / EBITDA
-8.47×

Profitability

Earnings per share
-$0.71
Return on assets
-32.83%
Return on equity
-131.92%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.84×
Current ratio
3.46×
Quick ratio
3.46×
Cash ratio
2.14×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.03M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for XGN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$18.42M$19.94M$17.31M$16.63M$17.24M$17.2M$15.5M$13.66M
Cost of revenue$7.58M$7.72M$7.1M$7.43M$7.17M$6.81M$6.38M$5.18M
Gross profit$10.84M$12.22M$10.21M$9.21M$10.08M$10.4M$9.12M$8.48M
Selling, general and administrative$12.83M$12.51M$12.07M$12.42M$11.45M$11.54M$11.2M$10.2M
Research and development$2.41M$1.43M$1.55M$1.76M$1.73M$1.48M$1.28M$1.66M
Total operating expenses$15.24M$13.94M$13.62M$14.18M$13.18M$13.03M$12.49M$11.86M
Operating income-$4.41M-$1.72M-$3.41M-$4.98M-$3.1M-$2.63M-$3.37M-$3.38M
Interest expense-$1.2M-$1.2M-$1.27M-$1.33M-$1.32M-$1.12M-$545K-$563K
Income before taxes-$6.34M-$3.2M-$3.93M-$4.66M-$7.09M-$4.4M-$3.75M-$3.75M
Income taxes-$1K$0$36K$13K$1K$37K$0$12K
Net income-$6.34M-$3.2M-$3.97M-$4.67M-$7.09M-$4.44M-$3.75M-$3.76M
Net income attributable to common shareholders-$6.34M-$3.2M-$3.97M-$4.67M-$7.09M-$4.44M-$3.75M-$3.76M
EBITDA-$2.74M-$1.09M-$2.82M-$4.38M-$2.03M-$2.16M-$2.93M-$2.97M
Basic earnings per share-$0.25-$0.13-$0.17-$0.20-$0.31-$0.21-$0.20-$0.20
Diluted earnings per share-$0.25-$0.13-$0.17-$0.20-$0.31-$0.21-$0.20-$0.20

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) reported a quarterly loss of $0.25 per share, missing the consensus estimate of $0.19, representing a -31.58% earnings surprise. Revenue of $18.42 million slightly exceeded expectations by 0.73%. The stock has outperformed the S&P 500 by 6.5% year-to-date, but the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical-Products industry ranks in the bottom 40% of Zacks industries.

Zacks Investment Research

Nephros Inc. (NEPH) Tops Q3 Earnings and Revenue Estimates

Nephros Inc. (NEPH) reported Q3 2026 earnings of $0.05 per share, beating consensus estimates of $0.02 and representing a 150% surprise. Revenue of $5.62 million also exceeded expectations by 6.68%. However, the stock has declined 33.4% year-to-date versus the S&P 500's 12.3% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, and operates in the Medical-Products industry which ranks in the bottom 36% of Zacks industries.

Zacks Investment Research

Zimmer Biomet (ZBH) Q3 Earnings and Revenues Beat Estimates

Zimmer Biomet reported Q3 2026 earnings of $1.90 per share, slightly beating consensus estimates of $1.89, with revenues of $2.06 billion exceeding expectations by 0.81%. However, the stock has underperformed the S&P 500 year-to-date, gaining 7.9% versus the market's 10.6%. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical-Products industry ranks in the bottom 37% of Zacks industries.

GlobeNewswire Inc.

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen Inc. (Nasdaq: XGN), a specialized autoimmune diagnostics company, announced it will participate in two investor conferences in November 2026 and will release its third quarter financial results on November 10, 2026. The company previously reported strong Q2 2026 results with record revenue, test volume, and trailing twelve-month average selling price, leading to increased full-year revenue guidance.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.